ObjectiveTo investigate the clinical effect of moxifloxacin or cefoperazone sodium tazobactam sodium in the treatment of patients with genitourinary system infection. Methods226 cases of genitourinary system infection were selected in our hospital from July 2012 to April 2014. Who were randomly divided into the moxifloxacin group and the cefoperazone sodium tazobactam sodium group, 113 cases in each group. The treatment of moxifloxacin and cefoperazone sodium tazobactam sodium for 1 weeks, respectively. The clinical efficacy, pathogenic rate, clearance rate and the incidence of adverse reactions were compared between the two groups. ResultsThe total effective rate of treatment in the moxifloxacin group (92.9%) was higher than the cefoperazone sodium tazobactam sodium group (80.5%). The clinical effect is superior to cefoperazone the sodium tazobactam sodium group (P＜0.01). There was no significant difference in the detection rate and clearance rate of Ureaplasma urealyticum (Uu) and Mycoplasma hominis (Mh) in the two groups (P＞0.05). The incidence of ADR in the moxifloxacin group was lower than that in the cefoperazone sodium tazobactam sodium group (P＜0.05). ConclusionMoxifloxacin is better than cefoperazone sodium tazobactam sodium in the treatment of genitourinary infection patients. The incidence of adverse reactions in patients is lower, and it is worth popularizing in clinical application.

无